Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETAPA I: P30-EPS Vaccine in Newly Diagnosed Glioblastoma
NCT05283109Phase 1Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of P30-EPS in glioma. Primary endpoint: Dose-limiting Toxicity at 2 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
P30-EPS
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05283109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283109.